<DOC>
	<DOCNO>NCT00947752</DOCNO>
	<brief_summary>The purpose study compare pain associated injection injection-site reaction approve formulation Glatiramer Acetate ( GA ) versus investigational formulation GA . In addition , investigator evaluate side effect two formulation GA .</brief_summary>
	<brief_title>Safety New Formulation Glatiramer Acetate</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<criteria>Subjects ≥ 18 year age diagnosis RRMS Currently inject GA 20mg/1.0mL per day subcutaneously ( SC ) minimum 90 day utilize autoject®2 glass syringe manual injection technique Willing switch autoject®2 glass syringe manual injection technique continue manual injection technique course study Willing able train seven site injection rotation . Subject must willing comply minimum five injection site rotation plan study Willing able complete procedure evaluation related study Willing continue follow usual injection site preparation routine adjunctive LISR management technique Willing able provide write informed consent Currently use treat another immunomodulating therapy ( IMT ) conjunction GA 30 day prior screen study Currently use intermittent pulse course corticosteroid route administration 30 day prior screen study . ( Corticosteroids prohibit duration study . ) Currently use investigational drug use treatment investigational agent 30 day prior screen study Presence history skin necrosis Known extensive dermatological condition could confound factor Pregnant planning pregnancy breastfeed Any physical condition impairs ability inject minimum five site rotation Not able willing complete daily diary Use parenteral medication ( e.g. , intramuscular , SC , intravenous , etc . ) either currently past 30 day prior screen study Any medical psychiatric condition would make subject unsuitable research , determine Investigator Previous participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Relapsing Remitting Multiple Sclerosis ( RRMS )</keyword>
	<keyword>Glatiramer Acetate ( GA )</keyword>
</DOC>